Novavax has started a phase 3 trial of its coronavirus vaccine. The trial has been delayed twice due to issues related to scaling up manufacturing of the shot.
Novavax now plans to enroll up to 30,000 participants in the U.S. and Mexico at over 100 sites. Two-thirds of the trial participants will receive two doses of the vaccine while the rest will get a placebo.
Although Novavax is months behind rivals such as Pfizer and Moderna who have already received emergency approvals for their vaccines, the company has supply agreements lined up with several countries and its vaccine could play a critical role in inoculating people around the world.
Novavax has also signed a $1.6 billion deal to supply the U.S. with 100 million doses of its shot.
Read the Reuters report.
